News
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
HealthDay on MSN12h
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse OutcomesAttention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world ...
Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback